PTIX vs. SONN, GNPX, YMTX, HOTH, LIPO, ADIL, KA, SNPX, LIXT, and ENVB
Should you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include Sonnet BioTherapeutics (SONN), Genprex (GNPX), Yumanity Therapeutics (YMTX), Hoth Therapeutics (HOTH), Lipella Pharmaceuticals (LIPO), Adial Pharmaceuticals (ADIL), Kineta (KA), Synaptogenix (SNPX), Lixte Biotechnology (LIXT), and Enveric Biosciences (ENVB). These companies are all part of the "pharmaceutical preparations" industry.
Protagenic Therapeutics (NASDAQ:PTIX) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Sonnet BioTherapeutics received 17 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users.
Sonnet BioTherapeutics has a consensus price target of $30.00, suggesting a potential upside of 1,530.43%. Given Sonnet BioTherapeutics' higher possible upside, analysts plainly believe Sonnet BioTherapeutics is more favorable than Protagenic Therapeutics.
In the previous week, Sonnet BioTherapeutics had 2 more articles in the media than Protagenic Therapeutics. MarketBeat recorded 2 mentions for Sonnet BioTherapeutics and 0 mentions for Protagenic Therapeutics. Protagenic Therapeutics' average media sentiment score of 0.00 beat Sonnet BioTherapeutics' score of -0.08 indicating that Protagenic Therapeutics is being referred to more favorably in the media.
Protagenic Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
8.0% of Protagenic Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. 37.0% of Protagenic Therapeutics shares are owned by insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Protagenic Therapeutics has a net margin of 0.00% compared to Sonnet BioTherapeutics' net margin of -11,187.19%. Protagenic Therapeutics' return on equity of -156.36% beat Sonnet BioTherapeutics' return on equity.
Protagenic Therapeutics has higher earnings, but lower revenue than Sonnet BioTherapeutics.
Summary
Sonnet BioTherapeutics beats Protagenic Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Protagenic Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protagenic Therapeutics Competitors List
Related Companies and Tools
